Douglas C Morran, Jianmin Wu, Nigel B Jamieson, Agata Mrowinska, Gabriela Kalna, Saadia A Karim, Amy Y M Au, Christopher J Scarlett, David K Chang, Malgorzata Z Pajak, Karin A Oien, Colin J McKay, C Ross Carter, Gerry Gillen, Sue Champion, Sally L Pimlott, Kurt I Anderson, T R Jeffry Evans, Sean M Grimmond, Andrew V Biankin, Owen J Sansom, Jennifer P Morton
OBJECTIVE: Pancreatic cancer is a leading cause of cancer-related death in the Western world. Current chemotherapy regimens have modest survival benefit. Thus, novel, effective therapies are required for treatment of this disease. DESIGN: Activating KRAS mutation almost always drives pancreatic tumour initiation, however, deregulation of other potentially druggable pathways promotes tumour progression. PTEN loss leads to acceleration of Kras(G12D)-driven pancreatic ductal adenocarcinoma (PDAC) in mice and these tumours have high levels of mammalian target of rapamycin (mTOR) signalling...
September 2014: Gut